VOLUME 21, NUMBER 2 FEBRUARY 2000

An Official Journal of The Society for Healthcare Epidemiology of America

PUBLISHED FOR THE SOCIETY BY SLACK INCORPORATED

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL


The Epidemiology of Contact Transmission: Beyond Semmelweis
EDWARD S. WONG, MD 77

ORIGINAL ARTICLE

A Prolonged Outbreak of *Pseudomonas aeruginosa* in a Neonatal Intensive Care Unit: Did Staff Fingernails Play a Role in Disease Transmission?
RONALD L. MOOLENAAR, MD; J. MICHAEL CRUTCHER, MD, MPH; VENUSTO H. SAN JOAQUIN, MD; LUCILLE V. SEWELL, RN, CIC; LORI C. HUTWAGNER, MS; LORETTA A. CARSON, MS; DENISE A. ROBISON, MS, MT; LAURI M.K. SMITHEE, MS; WILLIAM R. JARVIS, MD 80


ABSTRACTS

4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
CENTERS FOR DISEASE CONTROL AND PREVENTION
IN CONJUNCTION WITH THE 10TH ANNUAL MEETING OF THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA
COSPONSORED BY THE ASSOCIATION FOR PROFESSIONALS IN INFECTION CONTROL AND EPIDEMIOLOGY, INC, THE NATIONAL FOUNDATION FOR INFECTIOUS DISEASES, AND THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA 86



Continued inside.

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press



- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.[1]

- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.[2]

- Excellent safety profile[1]

Single-use tube (actual size)



The most frequently reported adverse events were headache (9%), rhinitis (6%), respiratory disorder (including upper respiratory tract congestion) (5%), pharyngitis (4%) and taste perversion (3%). Safety in children under 12 years of age has not been established in controlled clinical trials.

Contraindications … Do not use *Bactroban* Nasal in patients with known hypersensitivity to any of the constituents of the product.

Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. **2.** Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

Bactroban® Nasal *mupirocin calcium*

2% ointment for intranasal use

SB SmithKline Beecham Pharmaceuticals

BN2760 ©SmithKline Beecham, 1999 Philadelphia, PA

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE
Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:
(1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus.*
(2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
(3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS
Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS
AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS
General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See **DOSAGE AND ADMINISTRATION** in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to **40** times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m^2 basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m^2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See **CLINICAL PHARMACOLOGY** in complete prescribing information.)

ADVERSE REACTIONS
Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE
Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories,** San Antonio, TX 78215
Distributed by **SmithKline Beecham Pharmaceuticals,** Philadelphia, PA 19101
BRS-BN:L3

CLASSIFIED MARKETPLACE

ID/IM — Excellent opportunity. Assume an active practice in a Multi-Specialty Internal Medicine group. 60 miles from Manhattan. Fax CV: 914-294-5853.

High Level Disinfection Program For Reusable Medical Devices March 16th, 23rd, 30th, 2000

A distance learning AudioNet program will be conducted on the High Level Disinfection Program For Reusable Medical Devices. Participants can interact live with the presenters. CEU credits available. For more information, call (319)247-5095 to register.

The Robert C. Byrd Health Sciences Center/West Virginia University–Charleston Division invites applications for the position of Assistant/Associate Professor of Internal Medicine in Infectious Diseases. This is a non-tenure track position that is 50% supported by the hospital to oversee the Infection Control program at Charleston Area Medical Center (CAMC). CAMC is a 919-bed tertiary care teaching hospital which serves Southern West Virginia. Fifty-percent of the time is dedicated to Infectious Diseases/Internal Medicine. Prior experience in hospital epidemiology is desirable. The position will remain open until a qualified candidate is identified. We offer a competitive salary and excellent fringe benefits. West Virginia University is an affirmative action/equal opportunity employer. Please send curriculum vitae and names of at least 3 references to:

Greg Rosencrance, MD
Chairman
Department of Internal Medicine
Robert C. Byrd Health Sciences Center
West Virginia University - Charleston Division
3110 MacCorkle Avenue, SE
Charleston, WV 25304
or Email: jrosencr@wvu.edu

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR
Michael D. Decker, MD, MPH

MANAGING EDITOR
Susan Cantrell

STATISTICAL EDITOR
Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS
C. Glen Mayhall, MD
Gina Pugliese, RN, MS
William Schaffner, MD

ASSOCIATE EDITORS
Donald A. Goldmann, MD
Didier Pittet, MD, MS
Andreas Widmer, MD, MS

SECTION EDITORS

Beyond Infection Control: The New Hospital Epidemiology
Bryan P. Simmons, MD
Stephen B. Kritchevsky, PhD
Memphis, Tennessee
Wing Hong Seto, MD
Hong Kong

Disinfection and Sterilization
William A. Rutala, PhD, MPH
Chapel Hill, North Carolina

Emerging Infectious Diseases
Larry J. Strausbaugh, MD
Portland, Oregon
Robert W. Pinner, MD
Atlanta, Georgia

From the Laboratory
Marcus Zervos, MD
Royal Oak, Michigan
Fred C. Tenover, PhD
Atlanta, Georgia

Information Management
John A. Sellick, DO
Buffalo, New York

The International Perspective
Mary D. Nettleman, MD, MS
Richmond, Virginia

Issues in Surgery
James T. Lee, MD, PhD
St. Paul, Minnesota

Medical News
Gina Pugliese, RN, MS
Chicago, Illinois
Martin S. Favero, PhD
Irvine, California

Practical Healthcare Epidemiology
Loreen A. Herwaldt, MD
Iowa City, Iowa

SHEA News
Andreas Voss, MD, PhD
Nijmegen, The Netherlands

Statistics for Hospital Epidemiology
David Birnbaum, PhD, MPH
Sidney, British Columbia, Canada

Topics in Long-Term Care
Philip W. Smith, MD
Omaha, Nebraska

Topics in Occupational Medicine
David Weber, MD, MPH
Chapel Hill, North Carolina

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Graham A.J. Ayliffe, MD	Birmingham, United Kingdom
Neil L. Barg, MD	Yakima, Washington
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
John M. Boyce, MD	Providence, Rhode Island
Professor Dr. Ilja Braveny	Munich, Germany
Christian Brun-Buisson, MD	Creteil, France
Charles Bryan, MD	Columbia, South Carolina
Donald E. Craven, MD	Boston, Massachusetts
Sue Crow, MSN, RN, CIC	Shreveport, Louisiana
Franz Daschner, MD	Freiburg, Germany
Leigh G. Donowitz, MD	Charlottesville, Virginia
Charles E. Edmiston, Jr., PhD	Milwaukee, Wisconsin
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Victoria J. Fraser, MD	St. Louis, Missouri
Peter C. Fuchs, MD, PhD	Black Butte, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Robert Gaynes, MD	Atlanta, Georgia
Velvl Greene, PhD, MPH	Beer Sheva, Israel
David W. Gregory, MD	Nashville, Tennessee
David K. Henderson, MD	Bethesda, Maryland
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Marguerite McMillan Jackson, RN, PhD	San Diego, California
Janine Jagger, MPH, PhD	Charlottesville, Virginia
William R. Jarvis, MD	Atlanta, Georgia
Douglas S. Kernodle, MD	Nashville, Tennessee
Robert H. Latham, MD	Nashville, Tennessee
Lewis B. Lefkowitz, MD	Nashville, Tennessee
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
William J. Martone, MD	Bethesda, Maryland
Allison McGeer, MD	Toronto, Ontario, Canada
John E. McGowan, Jr., MD	Atlanta, Georgia
Jonathan L. Meakins, MD, DSc	Montreal, Quebec, Canada
Raf Mertens, MD	Brussels, Belgium
Robert R. Muder, MD	Pittsburgh, Pennsylvania
Joseph M. Mylotte, MD, CIC	Buffalo, New York
Lindsay Nicolle, MD	Winnepeg, Manitoba, Canada
Juhani Ojajärvi, MD	Helsinki, Finland
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Jan Evans Patterson, MD	San Antonio, Texas
Sindy M. Paul, MD	Trenton, New Jersey
Michael A. Pfaller, MD	Iowa City, Iowa
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Isaam Raad, MD	Houston, Texas
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
William E. Scheckler, MD	Madison, Wisconsin
Kent Sepkowitz, MD	New York City, New York
Denis Spelman, MD	Prahran Victoria, Australia
Michael L. Tapper, MD	New York, New York
Clyde Thornsberry, PhD	Brentwood, Tennessee
Professor Leonid P. Titov	Minsk, Republic of Belarus
Timothy R. Townsend, MD	Millwood, Virginia
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Wang Shu-Qun	Beijing, People's Republic of China
J. John Weems, Jr., MD	Greenville, South Carolina
Robert A. Weinstein, MD	Chicago, Illinois
Professor Dr. W. Weuffen	Greifswald, Germany
Sergio B. Wey, MD	São Paulo, Brazil
Rebecca Wurtz, MD	Evanston, Illinois

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(856) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Editorial Assistant
Aileen Schneider

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Tina Panna

Advertising Sales Coordinator
Jill Campise

Classified/Recruitment Sales Manager
Kathy Huntley

Classified/Recruitment Sales Representative
Katie Ford

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press

Vol. 21 No. 2 February 2000

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

CONTENTS

Continued from cover

INDEX OF ABSTRACTS FROM THE 4TH DECENNIAL INTERNATIONAL CONFERENCE ON NOSOCOMIAL AND HEALTHCARE-ASSOCIATED INFECTIONS 166

SHEA NEWS
ANDREAS VOSS, MD, PHD 176

To view abstracts of these articles, visit us on the Internet at http://www.slackinc.com/general/iche

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 2000 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-$110.00; Two years-$148.00; Three years-$181.00; Institutional: One year-$133.00; Two years-$183.00; Three years-$233.00. Fellows: $55.00 per year with proof of training status. Canada: $20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, $150.00 each year; Overseas air mail, $195.00. Single copies of current issues may be obtained for $15.00, United States and possessions; $20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (http://www.slackinc.com/general/iche/ichehome.htm). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).


REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of $1.00 per copy, plus $.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press

All The Facts For Your Immunization Program



Both textbooks are an official publication of
The Society for Healthcare Epidemiology of America (SHEA).

Immunizing Healthcare Workers: A Practical Approach

Edited by Gregory A. Poland, MD; William Schaffner, MD; Gina Pugliese, RN, MS
300 pp, Hard Cover, 2000, ISBN 1-55642-450-7, Order # 14507, **$109.00**

Immunizing Healthcare Workers: A Practical Approach is the first complete resource for dealing with the immunization of healthcare workers. You can find all of the latest information on successfully and safely implementing or updating your immunization program in this landmark book.

Inside you will find that for each of the vaccine-preventable diseases among workers, there is a discussion of disease risks in the healthcare setting, vaccine recommendations, special administration strategies, safety issues, discussion of unresolved issues, and answers to commonly asked questions. There are also case studies of sample programs in specific settings.

This phenomenal book contains the latest recommendations from the US Public Health Service Advisory Committees, Healthcare Infection Control Practices Advisory Committee (HICPAC), and the Advisory Committee on Immunization Practices (ACIP).

Read how the experts overcame obstacles while setting up immunization programs in their healthcare settings. With over 45 contributors to 32 chapters, **Immunizing Healthcare Workers: A Practical Approach** is an essential source for the latest information necessary to implement an effective immunization program.

Some Case Study Topics:

- Immunizing Providers and Staff in Physicians' Offices
- Vaccination of Healthcare Workers in Long-Term Care Facilities for the Elderly
- Immunization of Affiliating Students and Contract Home Healthcare Workers
- Immunization Strategies for Home Healthcare Personnel
- Immunization of Workers with Altered Host Defenses
- Vaccinating Unimmunized and Partially Immunized Workers
- Assessing Immunity and Exposures: Using a Computerized Surveillance System
- Managing Information in an Immunization Program
- The Internet: A Quick Guide to Vaccine & Immunization Information

ORDER FORM

Please send me ____ copies of **Immunizing Healthcare Workers: A Practical Approach** (Order# 14507) at **$109.00** each.

Please send me ____ copies of **A Practical Handbook for Hospital Epidemiologists** (Order # 13020) at **$65.00** each.

NJ residents add 6% sales tax $_____
Handling $ 4.50
Total $_____

Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____

E-mail: _____

❑ Check enclosed (Payable to SLACK Incorporated)

Charge my: ❑ ❑ VISA ❑ MasterCard

Account #: _____

Exp. date: _____ Signature _____

Prices are subject to change. Shipping charges may apply.

CODE: 1A448

Also Available

A Practical Handbook for Hospital Epidemiologists
Edited by: Loreen A. Herwaldt, MD and co-edited by Michael D. Decker, MD, MPH
448 pp, Soft Cover, 1998, ISBN 1-55642-302-0,
Order # 13020, **$65.00**

A Practical Handbook for Hospital Epidemiologists is the most complete source for practical advice on hospital epidemiology. It is intended to be a pragmatic guide that will assist both beginning and experienced practitioners in establishing and operating a successful hospital epidemiology program. This handbook will supplement the various scientific references already available for this field and will help hospital epidemiologists improve their practices.

Mail order form to:
SLACK Incorporated, Professional Book Division,
6900 Grove Road, Thorofare, NJ 08086-9447

Call: (800) 257-8290 or (856) 848-1000
Fax: (856) 853-5991
E-mail: orders@slackinc.com
World Wide Web Site: http://www.slackinc.com

https://doi.org/10.1017/S0195941700072829 Published online by Cambridge University Press